5Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis,2005,41:1455-1460.
6Rex JH,Pappas PG,Karchmer AW,et al. A randomized and blinded multicenter trial of high-dose fluconasole plus placebo versus fluconasole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis,2003,36:1221-1228.
7Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curt Drug Targets Infect Disord,2005 ,5 :203-210.
8Rees JR,Pinner RW,Hajjeh RA,et al. The epidemiologlcal features of invasive mycotic infections in the San Francisco Bay area, 1992-1993 :results of population-based laboratory active surveillance. Clin Infect Dis, 1998,27: 1138-1147.
9Nucci M,Marr KA. Emerging fungal diseases. Clin Infect Dis,2005,41:521-526.
5Bassetti M, Trecarichi E M, Righi E, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in halian university hospitals [J ]. Diagn Microbiol Infect Dis, 2007,58 ( 3 ) : 325-331.
6Redentz W H. Opportunistic infections immunoconpromised hosts [J]. J Aced Dematol, 1989,20(6):986.
